[go: up one dir, main page]

PE20142457A1 - Compuestos heterociclicos y sus usos - Google Patents

Compuestos heterociclicos y sus usos

Info

Publication number
PE20142457A1
PE20142457A1 PE2014001529A PE2014001529A PE20142457A1 PE 20142457 A1 PE20142457 A1 PE 20142457A1 PE 2014001529 A PE2014001529 A PE 2014001529A PE 2014001529 A PE2014001529 A PE 2014001529A PE 20142457 A1 PE20142457 A1 PE 20142457A1
Authority
PE
Peru
Prior art keywords
compounds
heterociclic
heterociclic compounds
phosphatidilinositol
ostoarthritis
Prior art date
Application number
PE2014001529A
Other languages
English (en)
Inventor
Minna Hue Thanh Bui
Timothy D Cushing
Lopez De Turiso Felix Gonzalez
Xiaolin Hao
Brian Lucas
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE20142457A1 publication Critical patent/PE20142457A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A COMPUESTOS HETEROCICLICOS DE FORMULAS: a), b), c), d), e), f) Y g). TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD SOBRE LA ENZIMA FOSFATIDILINOSITOL 3-CINASA (PI3K) Y SON UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, OSTOARTRITIS, PSORIASIS, ENTRE OTRAS
PE2014001529A 2012-04-04 2013-04-04 Compuestos heterociclicos y sus usos PE20142457A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261620270P 2012-04-04 2012-04-04

Publications (1)

Publication Number Publication Date
PE20142457A1 true PE20142457A1 (es) 2015-02-07

Family

ID=48142975

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001529A PE20142457A1 (es) 2012-04-04 2013-04-04 Compuestos heterociclicos y sus usos

Country Status (31)

Country Link
US (2) US8716290B2 (es)
EP (1) EP2834231B1 (es)
JP (1) JP2015512451A (es)
KR (1) KR20140139547A (es)
CN (1) CN104395305A (es)
AP (1) AP3611A (es)
AU (1) AU2013243506A1 (es)
CA (1) CA2869413A1 (es)
CL (1) CL2014002686A1 (es)
CO (1) CO7091181A2 (es)
CR (1) CR20140503A (es)
CY (1) CY1117487T1 (es)
DK (1) DK2834231T3 (es)
EA (1) EA201491823A1 (es)
ES (1) ES2577109T3 (es)
HR (1) HRP20160352T1 (es)
HU (1) HUE028762T2 (es)
IL (1) IL234822A0 (es)
MA (1) MA37472A1 (es)
ME (1) ME02473B (es)
MX (1) MX2014011970A (es)
PE (1) PE20142457A1 (es)
PH (1) PH12014502246A1 (es)
PL (1) PL2834231T3 (es)
RS (1) RS54716B1 (es)
SG (1) SG11201406316VA (es)
SI (1) SI2834231T1 (es)
SM (1) SMT201600211B (es)
TN (1) TN2014000412A1 (es)
WO (1) WO2013152150A1 (es)
ZA (1) ZA201407037B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068343A1 (en) * 2010-11-17 2012-05-24 Amgen Inc. Quinoline derivatives as pik3 inhibitors
MX2014011970A (es) * 2012-04-04 2015-05-12 Amgen Inc Compuestos heterociclicos y sus usos.
TW201625621A (zh) 2014-05-06 2016-07-16 艾恩傑股份有限公司 Ｐｉ３ｋ抑制劑之形式
JP6291601B2 (ja) 2014-07-04 2018-03-14 ルピン・リミテッド Ｐｉ３ｋ阻害剤としてのキノリジノン誘導体
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
WO2017155741A1 (en) 2016-03-05 2017-09-14 Zhejiang Vimgreen Pharma Ltd. Quinoline analogs as phosphatidylinositol 3-kinase inhibitors
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TWI853009B (zh) * 2019-03-29 2024-08-21 瑞士商先正達農作物保護公司 殺有害生物活性之二-醯胺化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
US5822910A (en) 1997-10-02 1998-10-20 Shewmake; I. W. Fishing line tensioning device
JP5065017B2 (ja) * 2004-06-28 2012-10-31 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ４，６位で二置換されたピリミジン及びプロテインキナーゼインヒビターとしてのそれらの使用
JP5732701B2 (ja) * 2007-03-23 2015-06-10 アムジエン・インコーポレーテツド ３−置換キノリンまたはキノキサリン誘導体およびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害剤としてのそれらの使用
EP2231641B1 (en) * 2007-12-21 2016-06-01 UCB Biopharma SPRL Quinoxaline and quinoline derivatives as kinase inhibitors
US20110294803A1 (en) * 2008-12-04 2011-12-01 Law Amanda J Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
US20100331306A1 (en) * 2009-06-25 2010-12-30 Amgen Inc. Heterocyclic compounds and their uses
JP2013514989A (ja) * 2009-12-18 2013-05-02 アムジエン・インコーポレーテツド 複素環式化合物およびその使用法
WO2012003271A1 (en) * 2010-07-02 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
MX2014011970A (es) * 2012-04-04 2015-05-12 Amgen Inc Compuestos heterociclicos y sus usos.

Also Published As

Publication number Publication date
SG11201406316VA (en) 2014-11-27
US20130267524A1 (en) 2013-10-10
WO2013152150A1 (en) 2013-10-10
US20140206694A1 (en) 2014-07-24
IL234822A0 (en) 2014-12-31
HRP20160352T1 (hr) 2016-05-06
US8835432B2 (en) 2014-09-16
MX2014011970A (es) 2015-05-12
RS54716B1 (sr) 2016-08-31
ME02473B (me) 2017-02-20
EA201491823A1 (ru) 2015-01-30
EP2834231A1 (en) 2015-02-11
PL2834231T3 (pl) 2016-07-29
AP3611A (en) 2016-02-29
HUE028762T2 (en) 2016-12-28
US8716290B2 (en) 2014-05-06
PH12014502246A1 (en) 2014-12-15
CL2014002686A1 (es) 2015-05-08
CN104395305A (zh) 2015-03-04
MA37472A1 (fr) 2016-09-30
AU2013243506A1 (en) 2014-10-09
AP2014007979A0 (en) 2014-09-30
CR20140503A (es) 2015-03-06
TN2014000412A1 (en) 2015-12-21
SI2834231T1 (sl) 2016-09-30
KR20140139547A (ko) 2014-12-05
EP2834231B1 (en) 2016-03-30
CY1117487T1 (el) 2017-04-26
SMT201600211B (it) 2016-08-31
CO7091181A2 (es) 2014-10-21
JP2015512451A (ja) 2015-04-27
DK2834231T3 (en) 2016-04-18
ES2577109T3 (es) 2016-07-13
CA2869413A1 (en) 2013-10-10
ZA201407037B (en) 2015-11-25

Similar Documents

Publication Publication Date Title
PE20142457A1 (es) Compuestos heterociclicos y sus usos
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CO6680667A2 (es) Derivados ester de ácido borónico cíclico y sus usos terapéuticos
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
MX2015003140A (es) Formulaciones de enzalutamida.
GT201400164A (es) Compuestos de imidazopirrolidinona
CL2011000668A1 (es) Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras.
GT201500251A (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
ECSP14013224A (es) Pirimidinas anilladas sustituidas y uso de las mismas
MX383590B (es) Inhibidores de kdm1a para el tratamiento de enfermedades.
MX376008B (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
GT201500069A (es) Piridinonas bicìclicas novedosas
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
PE20151023A1 (es) Triazolopirazinas
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
ECSP14030779A (es) Inhibidores del nampt
DOP2015000170A (es) Compuestos químicos
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CL2014002929A1 (es) Composicion que comprende ácido poliinosínico - policitidílico (poli (i:c) ) y un polimero portador; y sus usos para el tratamiento de infecciones de las vías respiratorias altas.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CR20130488A (es) Derivados de tieno [2,3-d]pirimidina y su uso para tratar arritmia
CL2018002848A1 (es) Formulaciones liquidas de fosfoplatino

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed